The Key Role of TNF-TNFR2 Interactions in the Modulation of Allergic Inflammation: A Review

Tumor necrosis factor-alpha (TNF) is a pleiotropic cytokine, which is thought to play a major role in the pathogenesis of inflammatory diseases, including allergy. TNF is produced at the early stage of allergen sensitization, and then continues to promote the inflammation cascade in the effector pha...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology Vol. 9; p. 2572
Main Authors: Ahmad, Suhana, Azid, Nor Azrini, Boer, Jennifer C, Lim, JitKang, Chen, Xin, Plebanski, Magdalena, Mohamud, Rohimah
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 09-11-2018
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor necrosis factor-alpha (TNF) is a pleiotropic cytokine, which is thought to play a major role in the pathogenesis of inflammatory diseases, including allergy. TNF is produced at the early stage of allergen sensitization, and then continues to promote the inflammation cascade in the effector phase of allergic reactions. Consequently, anti-TNF treatment has been proposed as a potential therapeutic option. However, recent studies reveal anti-intuitive effects of TNF in the activation and proliferative expansion of immunosuppressive Tregs, tolerogenic DCs and MDSCs. This immunosuppressive effect of TNF is mediated by TNFR2, which is preferentially expressed by immunosuppressive cells. These findings redefine the role of TNF in allergic reaction, and suggest that targeting TNF-TNFR2 interaction itself may represent a novel strategy in the treatment of allergy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Luis Graca, Universidade de Lisboa, Portugal
This article was submitted to Immunological Tolerance and Regulation, a section of the journal Frontiers in Immunology
Reviewed by: Olga Ucar, Independent Researcher, Manchester, United Kingdom; Marie-Claude Gaudreau, Bristol Myers Squibb, United States
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2018.02572